Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · May 26, 2024

Effectiveness of SGLT2 Inhibitors vs DPP-4 Inhibitors in Improvement of FLI in Patients With Type 2 Diabetes and Metabolic Dysfunction–Associated Steatotic Liver Disease

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan
Diabetes Obes Metab 2024 May 06;[EPub Ahead of Print], M Shikamura, A Takayama, M Takeuchi, K Kawakami

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading